ArticleGastro hep advances2026
FODMAP-Targeting Digestive Enzyme Blend for Management of Gastrointestinal Symptoms: A "Real-World" Pre-Post Intervention Cohort Study.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Irritable bowel syndrome (IBS) is a highly prevalent and morbid condition that causes tremendous symptom burden, impacts quality of life, and generates substantial healthcare costs. Current therapies are challenging to utilize and do not provide relief to many patients, creating a clear need for new innovation. In this study, we assess the efficacy of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)-hydrolyzing digestive enzymes in controlling IBS symptoms. Methods: We present a single-arm, open-label pre-post intervention cohort study among patients who purchased FODMAP-targeting enzymes online. Participants completed anonymous online surveys capturing demographics and symptom severity at baseline and 4-week follow-up. Results: After 4 weeks using the FODMAP-targeting digestive enzyme blend, 78.0% (95% confidence interval [CI]: [69.7%, 84.5%]) reported improvements in bloating and flatulence, 75.0% (95% CI: [61.2%, 85.1%]) reported improvements in diarrhea (IBS-D only), 72.7% (95% CI: [51.9%, 86.9%]) reported improvements in constipation (IBS-C only), and 65.3% (95% CI: [56.3%, 73.2%]) reported improvements in abdominal pain. Significant improvements in overall IBS symptom severity were observed ( Conclusion: While further research is needed, this is a promising first report that enzymatic digestion may have the potential to decrease the burden of disorders of the gut-brain interaction, including IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.